Patent ID: 8088412

Claim:
A chemotherapeutic composition for treating and/or inhibiting cancer configured for administration, the composition comprising: a pharmaceutically acceptable carrier; and a nanoconjugate configured for preferential intralymphatic accumulation after subcutaneous, percutaneous, intradermal, mucosal, submucosal, interstitial, intrafat, peritumoral, or intramuscular injection administration, the nanoconjugate having a dimension of 10 nm to 80 nm and consisting essentially of: a nanocarrier configured for preferential intralymphatic accumulation after administration, the nanocarrier being hyaluronan; and a plurality of chemotherapeutic agents coupled to the nanocarrier, the chemotherapeutic agents comprising cisplatin, wherein the nanoconjugate is formed by mixing the hyaluronan and the cisplatin in an aqueous-based solution such that the hyaluronan and cisplatin forms an ionic bond without any additional conjugation-mediating additives, and further wherein the nanocarrier is loaded with the cisplatin in an amount of from 25% to about 50% w/w.